Terns Pharmaceuticals Closes $747.5 Million Public Offering to Advance BCR-ABL Inhibitor TERN-701
核心洞察
Terns Pharmaceuticals successfully closed an underwritten public offering of 18,687,500 shares at $40.00 per share, raising gross proceeds of $747.5 million.
The clinical-stage oncology company will use the funds to advance research, clinical trials, and manufacturing of TERN-701, a highly selective allosteric BCR-ABL (搜索) inhibitor.
TERN-701 is being developed as a potential best-in-disease treatment for chronic myeloid leukemia (搜索) (CML (搜索)) with improved efficacy, safety, and convenience over existing therapies.
Terns Pharmaceuticals has successfully completed a substantial $747.5 million public offering to fund the development of its lead oncology program TERN-701, a novel BCR-ABL (搜索) inhibitor targeting chronic myeloid leukemia (搜索) (CML (搜索)). The clinical-stage oncology company closed the underwritten public offering on December 11, 2025, selling 18,687,500 shares of common stock at $40.00 per share.
Major Funding Milestone for Cancer Drug Development
The offering included 2,437,500 shares sold through the full exercise of underwriters' option to purchase additional shares. Jefferies (搜索), TD Cowen (搜索), and Leerink Partners (搜索) served as lead book-running managers, while Mizuho, Citizens Capital Markets, and Oppenheimer & Co. acted as co-managers for the transaction.
The substantial funding represents a significant milestone for the Foster City, California-based company, which describes itself as "reimagining known biology to deliver high impact medicines." The net proceeds will specifically support research, clinical trials, development, and manufacturing of key product candidates, with particular focus on TERN-701.
TERN-701: Targeting Unmet Medical Needs in CML
TERN-701 represents Terns' lead program and is characterized as a highly selective, allosteric BCR-ABL (搜索) inhibitor. According to the company, the drug candidate has "a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML (搜索)."
The BCR-ABL (搜索) protein is a well-established therapeutic target in chronic myeloid leukemia (搜索), formed by a chromosomal translocation that creates an oncogenic fusion protein driving cancer cell proliferation. Current treatments for CML (搜索) include several approved BCR-ABL inhibitors, but the company suggests TERN-701's allosteric mechanism and selectivity profile may offer advantages over existing therapies.
Strategic Use of Capital
Beyond TERN-701 development activities, Terns plans to allocate portions of the funding toward "initial activities in preparation for the potential future commercial launch of TERN-701 and for working capital and general corporate purposes." This indicates the company is beginning to consider commercialization strategies alongside its ongoing clinical development efforts.
The public offering was conducted under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on December 9, 2025, and became effective immediately upon filing.
Market Context and Forward Outlook
The successful completion of this large-scale funding round demonstrates investor confidence in Terns' oncology pipeline and the potential of TERN-701. The company had initially announced a proposed offering of $400 million with an option for an additional $60 million, but the final offering size of $747.5 million significantly exceeded these initial parameters.
As a clinical-stage company, Terns faces the typical risks associated with drug development, including uncertainties related to clinical trial outcomes, regulatory approval processes, and market competition. The company has noted that forward-looking statements regarding TERN-701's potential benefits are subject to significant uncertainties and risks that could cause actual results to vary materially from expectations.